WuXi Biologics (2269) 44th Annual J.P. Morgan Healthcare Conference summary

Business model and growth strategy

• Operates a scaled, integrated CRDMO platform offering end-to-end biologics development and manufacturing services, supporting modalities like mAbs, bi- & multi-specifics, ADCs, fusion proteins, and vaccines.

• Focuses on complex modalities such as bispecifics and ADCs, which now make up two-thirds of the portfolio and are the fastest-growing, highest-margin segments, contributing nearly 20% of revenue.

• Achieved a record high of 209 new integrated projects signed last year, with about half from U.S. clients.

• Maintains a robust project funnel nearing 1,000 molecules, with a pipeline including 196 bi- & multi-specifics and 252 ADC projects, supporting sustained growth.

• High client retention and project stickiness, with a 90%+ conversion from development to manufacturing.

Financial performance and outlook

• Royalties, milestones, and upfront payments contributed 20% of profit last year, expected to rise to 25% in five years, with milestone and upfront payments projected to grow at a 30% CAGR.

• Biotech contracts generated $4 billion last year, with 20 programs carrying 5%-10% royalties and potential milestones exceeding $4B.

• Manufacturing revenue is set to accelerate, with PPQ numbers tripling, 28 PPQs completed in 2025, 34 scheduled for 2026, and a 99% success rate.

• Qatar site expected to contribute $500–$800 million in revenue by 2030.

• On track for strong top and bottom line growth in 2025 and 2026, with multiple blockbuster launches anticipated.

Technology leadership and digital transformation

• Invested early in bispecific and CD3 platforms, now generating hundreds of millions in IP income and driving differentiated partner pipelines.

• Launched proprietary cell line technologies, reducing development time from nine to two months and enabling rapid, high-titer production.

• Developed digital and AI-driven platforms, including DaVinci Client Portal, BioFoundry, and PatroLab™, enhancing client experience, speed, and operational efficiency.

• Enabled IV-to-SubQ conversion, supporting at-home administration and higher patient convenience.

• Disposable manufacturing proven cost-competitive and environmentally friendly.